Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The expression level of BAALC -associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Brunet, Salut|||0000-0003-0491-1672
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Cordeiro, A.
  • Tormo, Mar|||0000-0001-9622-1649
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Arnan, Montserrat
  • Heras, Inmaculada
  • Gallardo, David|||0000-0003-1615-4592
  • Bargay, Joan|||0000-0002-6739-3916
  • Queipo de Llano, M. Paz
  • Salamero, Olga|||0000-0003-3237-0025
  • Martí, J. M.
  • Sampol, Antonia|||0000-0001-7465-6203
  • Pedro, Carme
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Castellano, J. J.
  • Nomdedeu, Meritxell
  • Risueño, Ruth M.|||0000-0003-4048-9536
  • Sierra, Jorge|||0000-0002-7966-0356
  • Monzó, Mariano
  • Navarro Ponz, Alfons
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P =0.0025), shorter leukemia-free survival (P =0.026) and higher cumulative incidence of relapse (P =0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P =0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic impact of circulating plasma cells in patients with multiple myeloma, implications for plasma cell leukemia definition

  • Granell, Miquel|||0000-0002-0366-3673
  • Calvo, Xavier|||0000-0001-7934-9130
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Martínez, Clara Mª
  • Teixidó, Montserrat
  • Gimenez, Mª Teresa
  • Senín, Alicia
  • Sanz, Patricia
  • Campoy, Desirée
  • Vicent, Ana
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Sierra, Jorge|||0000-0002-7966-0356
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Fernandez de Larrea Rodriguez, Carlos
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×10 9 /L vs. 214×10 9 /L, P <0.0001) and higher bone marrow plasma cells (median 53% vs. 36%, P =0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Conde, M. Isabel Prieto
  • Llop, Marta
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Prieto Conde, M. Isabel
  • Llop, Marta
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Montesinos, Pau|||0000-0002-3275-5593
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
In recent years, several attempts have been made to identify novel prognostic markers in patients with intermediate-risk acute myeloid leukemia (IR-AML), to implement risk-adapted strategies. The non-receptor tyrosine kinases are proteins involved in regulation of cell growth, adhesion, migration and apoptosis. They associate with metastatic dissemination in solid tumors and poor prognosis. However, their role in haematological malignancies has been scarcely studied. We hypothesized that PTK2/FAK, PTK2B/PYK2, LYN or SRC could be new prognostic markers in IR-AML. We assessed PTK2, PTK2B, LYN and SRC gene expression in a cohort of 324 patients, adults up to the age of 70, classified in the IR-AML cytogenetic group. Univariate and multivariate analyses showed that PTK2B, LYN and PTK2 gene expression are independent prognostic factors in IR-AML patients. PTK2B and LYN identify a patient subgroup with good prognosis within the cohort with non-favorable FLT3/NPM1 combined mutations. In contrast, PTK2 identifies a patient subgroup with poor prognosis within the worst prognosis cohort who display non-favorable FLT3/NPM1 combined mutations and underexpression of PTK2B or LYN. The combined use of these markers can refine the highly heterogeneous intermediate-risk subgroup of AML patients, and allow the development of risk-adapted post-remission chemotherapy protocols to improve their response to treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy

  • Alvarez-Fernández, Carmen|||0000-0003-0060-0447
  • Escribà Garcia, Laura|||0000-0002-3306-310X
  • Vidal, Silvia|||0000-0002-3909-6682
  • Sierra, Jorge|||0000-0002-7966-0356
  • Briones Meijide, Javier|||0000-0003-2750-3735
Immunotherapy based on the adoptive transfer of gene modified T cells is an emerging approach for the induction of tumor-specific immune responses. Memory stem T cells, due to their enhanced antitumor and self-renewal capacity, have become potential candidate for adoptive T cell therapy of cancer. Methods to generate memory stem T cells ex vivo rely on CD3/CD28 costimulation and the use of cytokines such as IL-7 and IL-15 during the entire culture period. However, a strong costimulation may induce differentiation of memory stem T cells to effector memory T cells. Here we show that manipulation of the length of the costimulation and addition of IL-21 enhance the ex vivo expansion of memory stem T cells. Purified naïve T cells from healthy donors were cultured in the presence of anti-CD3/CD28 coated beads, IL-7, IL-15 and/or IL-21 (25 ng/ml). T cells phenotype from the different memory and effector subpopulations were analyzed by multiparametric flow cytometry. A short anti-CD3/CD28 costimulation of naïve T cells, combined with IL-7 and IL-15 significantly increased the frequencies of CD4 + and CD8 + memory stem T cells ex vivo, compared to a prolonged costimulation (34.6 ± 4.4 % vs 15.6 ± 4.24 % in CD4 + ; p = 0.008, and 20.5 ± 4.00 % vs 7.7 ± 2.53 % in CD8 + ; p = 0.02). Moreover, the addition of IL-21 to this condition further enhanced the enrichment and expansion of CD4 + and CD8 + memory stem T cells with an increase in the absolute numbers (0.7 × 10 6 ± 0.1 vs 0.26 × 10 6 ± 0.1 cells for CD4 + ; p = 0.002 and 1.1 × 10 6 ± 0.1 vs 0.27 × 10 6 ± 0.1 cells for CD8 + ; p = 0.0002; short + IL-21 vs long). These new in vitro conditions increase the frequencies and expansion of memory stem T cells and may have relevant clinical implications for the generation of this memory T cell subset for adoptive cell therapy of patients with cancer. The online version of this article (doi:10.1186/s12967-016-0973-y) contains supplementary material, which is available to authorized users.